References:
- .Krainer J, Siebenhandl S, Weinhäusel A. Systemic autoinflammatory
diseases. J Autoimmun. 2020 May;109:102421. doi:
10.1016/j.jaut.2020.102421
- Tuladhar S, Kanneganti T. NLRP12 in innate immunity and inflammation.
Mol Asp Med. 2020;76:100887. https://doi.org/10.1016/j.mam.2020.100887
- Wang H. NLRP12-associated systemic autoinflammatory diseases in
children Pediatric Rheumatology (2022) 20:9
https://doi.org/10.1186/s12969-022-00669-8
- Henter JI, Horne A, Arico M, et al. HLH-2004: Diagnostic and
therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr
Blood Cancer. 2007;48:124-31. DOI: 10.1002/pbc.21039.
- Xia X, Dai C, Zhu X, et al. Identification of a Novel NLRP12 Nonsense
Mutation (Trp408X) in the Extremely Rare Disease FCAS by Exome
Sequencing. PLoS One. 2016;11:e0156981.
https://doi.org/10.1371/journal.pone.0156981
- Kostik MM, Suspitsin EN, Guseva MN, et al. Multigene sequencing
reveals heterogeneity of NLRP12-related autoinflammatory disorders.
Rheumatol Int. 2018;38:887-93. DOI: 10.1007/s00296-018-4002-8
- Borghini S, Tassi S. Clinical Presentation and Pathogenesis of
Cold-Induced Autoinflammatory Disease in a Family With Recurrence of
an NLRP12 Mutation. Arthritis Rheum. 2011; 63(3): 830–839. doi:
10.1002/art.30170
- Normand S, Waldschmitt N, Neerincx A, et al. Proteasomal degradation
of NOD2 by NLRP12 in monocytes promotes bacterial tolerance and
colonization by enteropathogens. Nat Commun. 2018;9(1):5338.
https://doi.org/10.1038/s41467-018-07750-5.
- Kareva L, Stavrik K, Mironska K. Cryopyrin-Associated Periodic
Syndromes and Treatment Options. Open Access Maced J Med Sci. 2020 Sep
03; 8(F):241-245. https://doi.org/10.3889/oamjms.2020.5024
- Chinn IK, Eckstein OS, Peckham-Gregory EC, et al. Genetic and
mechanistic diversity in pediatric hemophagocytic lymphohistiocytosis.
Blood. 2018;132:89-100. DOI: 10.1182/blood-2017-11-814244
Figure 1: Left - A) maculopapular rash with target lesions in upper
limbs at initial clinical presentation; B) maculopapular rash with
target lesions in both upper and lower limbs during relapse. Right – C)
Overview of the NLRP12 activity in the canonical and
non-canonical NF-KB pathways, showing NLRP12 role in inhibiting
IRKA1 and IKK, leading to the control in the production of inflammatory
cytokines, like IL-1β. Loss of function (LoF) mutations stop that
inhibition leading to an increased transcription of pro-inflammatory
cytokines, which promotes inflammation; D) Role of IL-1 receptor
antagonist (IL-1RA) as therapeutic drug that blocks the IL-1 receptor
(IL-1R), inhibiting the action of IL-1 and controlling inflammation in
these patients.
For this manuscript Figure 1 Right was created with BioRender.com and a
publication license was obtained.
Table 1: Laboratory studies: immunological and infectious diseases
screening during hospital admission